Mycobacterium indicus pranii is a potent immunomodulator for a recombinant vaccine against human chorionic gonadotropin

Purswani, Shilpi; Talwar, G.P.; Vohra, Richa; Pal, Rahul; Panda, Amulya K.; Lohiya, N. K.; Gupta, Jagdish C.

doi:10.1016/j.jri.2011.06.099

Cited by 26 publications

(22 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Initially evaluated as an immune-therapeutic against leprosy, MIP has generated a lot of interest because of its strong immunomodulatory activity and the promising results obtained against tuberculosis, 9,31 . In our previous studies, where MIP was evaluated as a vaccine candidate against tuberculosis, we found significantly higher protection in MIP-treated animals compared with those treated with BCG.…”

Section: Discussionmentioning

confidence: 99%

Mycobacterium indicus pranii and Mycobacterium bovis BCG lead to differential macrophage activation in Toll‐like receptor‐dependent manner

et al. 2014

View full text Add to dashboard Cite

SummaryMycobacterium indicus pranii (MIP) is an atypical mycobacterial species possessing strong immunomodulatory properties. It is a potent vaccine candidate against tuberculosis, promotes Th1 immune response and protects mice from tumours. In previous studies, we demonstrated higher protective efficacy of MIP against experimental tuberculosis as compared with bacillus Calmette-Gu erin (BCG). Since macrophages play an important role in the pathology of mycobacterial diseases and cancer, in the present study, we evaluated the MIP in live and killed form for macrophage activation potential, compared it with BCG and investigated the underlying mechanisms. High levels of tumour necrosis factor-a, interleukin-12p40 (IL-12p40), IL-6 and nitric oxide were produced by MIP-stimulated macrophages as compared with BCG-stimulated macrophages. Prominent up-regulation of co-stimulatory molecules CD40, CD80 and CD86 was also observed in response to MIP. Loss of response in MyD88-deficient macrophages showed that both MIP and BCG activate the macrophages in a MyD88-dependent manner. MyD88 signalling pathway culminates in nuclear factor-jB/activator protein-1 (NF-jB/AP-1) activation and higher activation of NF-jB/AP-1 was observed in response to MIP. With the help of pharmacological inhibitors and Toll-like receptor (TLR) -deficient macrophages, we observed the role of TLR2, TLR4 and intracellular TLRs in MIP-mediated macrophage activation. Stimulation of HEK293 cells expressing TLR2 in homodimeric or heterodimeric form showed that MIP has a distinctly higher level of TLR2 agonist activity compared with BCG. Further experiments suggested that TLR2 ligands are well exposed in MIP whereas they are obscured in BCG. Our findings establish the higher macrophage activation potential of MIP compared with BCG and delineate the underlying mechanism.

show abstract

Section: Discussionmentioning

confidence: 99%

Mycobacterium indicus pranii and Mycobacterium bovis BCG lead to differential macrophage activation in Toll‐like receptor‐dependent manner

et al. 2014

View full text Add to dashboard Cite

show abstract

“…148, 149 The antibody titers generated in different strains of mice were several fold higher than the protective threshold of 50 ng/ml in women. 149 Further studies are awaited to ascertain the immunogenicity and contraceptive efficacy of this recombinant protein in women.…”

Section: Contraceptive Vaccines Based On Hcgmentioning

confidence: 99%

“…149 Further studies are awaited to ascertain the immunogenicity and contraceptive efficacy of this recombinant protein in women.…”

Section: Contraceptive Vaccines Based On Hcgmentioning

confidence: 99%

Milestones in contraceptive vaccines development and hurdles in their application

Gupta

Shrestha

Minhas

2013

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

“…). It is a nonpathogenic, fast‐growing mycobacterium that acts as a potent adjuvant to boost antibody titers . Although live MiP is a stronger inducer of immune responses, adjuvanticity is retained in the killed, autoclaved state .…”

Section: Revival Of the Vaccinementioning

confidence: 99%

A unique vaccine for control of fertility and therapy of advanced‐stage terminal cancers ectopically expressing human chorionic gonadotropin

Talwar¹

2013

Annals of the New York Academy of Sciences

View full text Add to dashboard Cite

Human chorionic gonadotropin (hCG) appears soon after fertilization of the egg and plays a critical role in implantation of the embryo leading to the beginning of pregnancy. Vaccines developed against hCG prevent pregnancy without impairment of ovulation and disturbance of menstrual regularity. A new recombinant vaccine hCGβ-LTB has been developed that is highly immunogenic in various strains of mice and intended for the control of fertility in women. An additional use of this vaccine is likely to be treatment of advanced-stage cancers that ectopically express hCG.

show abstract

Mycobacterium indicus pranii is a potent immunomodulator for a recombinant vaccine against human chorionic gonadotropin

Cited by 26 publications

References 21 publications

Mycobacterium indicus pranii and Mycobacterium bovis BCG lead to differential macrophage activation in Toll‐like receptor‐dependent manner

Mycobacterium indicus pranii and Mycobacterium bovis BCG lead to differential macrophage activation in Toll‐like receptor‐dependent manner

Milestones in contraceptive vaccines development and hurdles in their application

A unique vaccine for control of fertility and therapy of advanced‐stage terminal cancers ectopically expressing human chorionic gonadotropin

Contact Info

Product

Resources

About